The 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past year. As of today (2025-07-24), Response Genetics's 1-Year Sortino Ratio is -3.46.
Competitive Comparison of Response Genetics's 1-Year Sortino Ratio
For the Diagnostics & Research subindustry, Response Genetics's 1-Year Sortino Ratio, along with its competitors' market caps and 1-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics's 1-Year Sortino Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's 1-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Response Genetics's 1-Year Sortino Ratio falls into.
Response Genetics 1-Year Sortino Ratio Calculation
The 1-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio over the past year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 1-Year Sortino Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the downside risks over one year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Response Genetics (OTCPK:RGDXQ) 1-Year Sortino Ratio Explanation
The 1-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by the standard deviation of negative returns over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Response Genetics 1-Year Sortino Ratio Related Terms
Thank you for viewing the detailed overview of Response Genetics's 1-Year Sortino Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDXQ has been successfully added to your